Selective local postoperative radiotherapy for T3-T4 N0 laryngeal cancer

Strahlenther Onkol. 2022 Nov;198(11):1025-1031. doi: 10.1007/s00066-022-01999-y. Epub 2022 Sep 8.

Abstract

Purpose: We aimed to investigate the appropriate postoperative radiotherapy dose and selective volume in T3-4 N0 laryngeal cancer patients treated with either total or partial laryngectomy.

Methods: Patients who received radiotherapy for locally advanced (T3-T4) and pathologic node-negative (N0) squamous cell laryngeal cancer were retrospectively evaluated. Radiotherapy was applied to median 60 Gy (range 54-60 Gy) as selective local radiotherapy (±stoma). The local treatment areas included postoperative bed + laryngeal area for patients with a partial laryngectomy, and the postoperative bed only for patients with total laryngectomy.

Results: The median follow-up time was 59 months and 52 patients were included. The 2‑year, 5‑year, and 8‑year locoregional recurrence controls (LRC) were 95.6%. The 2‑year and 5‑year OS rates were 93.8% and 78.9%, respectively. The 5‑year OS for age < 60 years was 95.8%, for above 60 years 56.5%.

Conclusion: Our data suggest that local selective irradiation to the postoperative bed + stoma is enough in patients with T3-4 N0 laryngeal cancer without applying elective nodal irradiation.

Keywords: Laryngeal cancer; Postoperative treatment; Radiotherapy; Selective treatment; Total or partial laryngectomy.

MeSH terms

  • Carcinoma, Squamous Cell* / pathology
  • Carcinoma, Squamous Cell* / radiotherapy
  • Carcinoma, Squamous Cell* / surgery
  • Humans
  • Laryngeal Neoplasms* / pathology
  • Laryngeal Neoplasms* / radiotherapy
  • Laryngeal Neoplasms* / surgery
  • Laryngectomy
  • Middle Aged
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Staging
  • Retrospective Studies